Re: Farmas USA
AZN
-15% premarket after the trial of its new lung cancer drug failed to reach its "endpoints" for progression free survival - the length for which people go without their condition worsening.
The study, known as Mystic, featured an immunotherapy drug that AstraZeneca hoped would eventually be adopted as a first line treatment in preference to chemotherapy, casting doubt on a central part of the company's growth plans.
https://seekingalpha.com/news/3281925-immunotherapy-setback-astrazeneca?ifp=0
«Después de nada, o después de todo/ supe que todo no era más que nada.»